Adrian O’Dowd , 2025-04-14 15:11:00
The UK National Institute for Health and Care Excellence has recommended a targeted twice daily drug treatment that could help around 3000 women a year with advanced breast cancer in England and Wales.
In final draft guidance published on 11 April,1 NICE said it was recommending capivasertib (also called Truqap) with fulvestrant as an option for around 1100 adults with hormone receptor positive HER2-negative breast cancer that has certain genetic mutations and that has spread.
The Institute of Cancer Research said that the new drug was also suitable for patients whose tumours have mutations or alterations in the PIK3CA, AKT1, or PTEN genes, found in around half …